Drug Standards
Medchemexpress LLC Neratinib | 698387-09-6 | MFCD09752958 | 99.9% | 557.0 g/mol | 1 ML
Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively.
- Inhibits proliferation of cell lines with high HER-2 levels.
- Less active in cell lines not expressing HER-2 or EGFR.
- Arrests cell cycle at G1-S phase.
- Causes inhibition of MAPK and Akt phosphorylation, down-regulation of cyclin D1 levels, and induction of p27.
- Shows anticancer activities against cancer cells expressing high levels of HER-2 or EGFR in vivo.
- Reduces tumor growth in a dose-dependent manner in xenografts.
- Inhibits phosphorylation of HER-2 in xenografts.
Medchemexpress LLC Proguanil (hydrochloride) | 637-32-1 | 99.2% | 100 MG
Proguanil hydrochloride is an antimalarial proagent that is metabolized into its active metabolite, Cycloguanil. It acts as a dihydrofolate reductase (DHFR) inhibitor, primarily used in research to study malaria and its related pathways.
- Functions as a dihydrofolate reductase (DHFR) inhibitor
- Metabolized into active form Cycloguanil for antimalarial activity
- Synergistic effects when combined with Atovaquone
- Active against gametocytes and pre-erythrocytic stages of malaria parasites
- Reversibly inhibits 5-HT3 receptor responses
- Intended for research use only
Medchemexpress LLC Tofacitinib citrate | 540737-29-9 | 99.94% | 50 MG
Tofacitinib citrate is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively. It also exhibits antibacterial, antifungal, and antiviral activities.
- Orally available JAK3/2/1 inhibitor
- Antibacterial activity
- Antifungal activity
- Antiviral activity
![Medchemexpress LLC 4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine | 952518-97-7 | MFCD20683197 | 97.0% | 185.19 g/mol | C9H7N5 | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000209080.png-250.jpg)
Medchemexpress LLC 4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine | 952518-97-7 | MFCD20683197 | 97.0% | 185.19 g/mol | C9H7N5 | 25 MG
Ruxolitinib impurity-1 (CAS 952518-97-7) is a characterized impurity of ruxolitinib used as an analytical reference standard for impurity profiling and safety analysis. It is typically supplied in small vial quantities for laboratory analytical use.
- Purity: 97.0%.
- CAS number: 952518-97-7.
- Molecular formula: C9H7N5.
- Molecular weight: 185.19 g/mol.
- Intended use: impurity profiling and safety analysis.
- Pack size: 25 MG.
Medchemexpress LLC Tofacitinib impurity 4 | 384338-23-2 | 96.0% | 218.34 | 50 MG
Tofacitinib impurity 4 is an impurity of Tofacitinib. This product is designed for research use only.
- Appearance: Liquid
- Color: Colorless to light yellow
- Shipping: Room temperature in continental US; may vary elsewhere
- Storage: Pure form can be stored at -20°C for 3 years or 4°C for 2 years; in solvent, it can be stored at -80°C for 6 months or -20°C for 1 month
Medchemexpress LLC Tofacitinib impurity 2 | 95.4% | 436.69 | 250 MG
Tofacitinib impurity 2 is an impurity of Tofacitinib. It is intended for research use only and not for sale to patients.
- Purity: 95.42%
- Molecular weight: 436.69
- Formula: C28H44N4
- Appearance: Liquid
- Shipping: Room temperature in continental US; may vary elsewhere.
- Storage: 4°C, protect from light. In solvent: -80°C for 6 months; -20°C for 1 month (protect from light).
![eMolecules 183133-96-2 | CABAZITAXEL | AstaTech | MFCD18827611 | 835.944 | C45H57NO14 | 98.000 | CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C | 0.25g | 484551615](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000488876.jpg-250.jpg)
eMolecules 183133-96-2 | CABAZITAXEL | AstaTech | MFCD18827611 | 835.944 | C45H57NO14 | 98.000 | CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C | 0.25g | 484551615
CABAZITAXEL | AstaTech | 183133-96-2 | MFCD18827611 | 835.944 | C45H57NO14 | 98.000 | CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C | 0.25g | 484551615
Medchemexpress LLC Fenticonazole Nitrate | 73151-29-8 | 98.86% | 100 MG
Fenticonazole Nitrate is an antifungal imidazole ring derivative that primarily functions by hindering ergosterol integration, leading to the destruction of the cytoplasmic outer membrane. This action makes it effective against a range of pathogens.
- Effective against Gram-positive bacteria, mycoses, and vaginal candidiasis
- Active against dermatophyte pathogens, Malassezia furfur, and Candida albicans
- Used locally in the treatment of vulvovaginal candidiasis
- For research use only
Medchemexpress LLC Proguanil hydrochloride | 637-32-1 | 99.2% | 50 MG
Proguanil hydrochloride | 637-32-1 | 99.2% | 50 MG
Apexbio Technology LLC Flavopiridol hydrochloride 131740-09-5 10mM (in 1mL DMSO)
Flavopiridol hydrochloride is a selective inhibitor of cyclin-dependent kinases (CDKs) specifically targeting CDK1 CDK2 CDK4 and CDK6 with reported IC50 values approximately 41 nM and CDK7 with an IC50 of about 300 nM Additionally it has been observed to inhibit EGFR and protein kinase A at micromolar concentrations By inhibiting CDK activity flavopiridol hydrochloride disrupts cell cycle progression inducing G1 phase arrest as demonstrated in breast cancer cell lines Furthermore its capacity to inhibit phosphorylation of Rb protein and suppress anti-apoptotic proteins such as Mcl-1 and XIAP facilitates apoptosis in lymphoma cell models Flavopiridol hydrochloride is utilized in preclinical studies of cell cycle regulation apoptosis signaling and cancer research including experiments using xenograft tumor models in mice
U.S. Pharmacopeia Zoledronic Acid Related Compound B | 1627731-61-6 | MFCD32706932 | 30 mg
Zoledronic Acid Related Compound B | Mol Wt: 476.10 | 1627731-61-6 | MFCD32706932 | 30 mg
Cayman Chemical 6-AmInocaproIc AcId 50g
An inhibitor of the plasmin activating enzymes streptokinase, fibrinokinase, and urokinase (IC50s = ~8 μM for all in an enzyme assay); selective for plasmin activating enzymes over trypsin (IC50 = >500 μM); inhibits in vitro plasmin activation and fibrinolysis in a dose-dependent manner; reduces ex vivo fibrinolysis in dog plasma following i.p. administration at doses ranging from 20-100 mg/kg